BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
ADCETRIS (brentuximab vedotin) by Pfizer is cd30-directed antibody interactions [moa]. Approved for hodgkin lymphoma, anaplastic large cell lymphoma. First approved in 2011.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADCETRIS (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) that binds to CD30 antigen on tumor cells and delivers cytotoxic payload, inducing cell death. It is approved for multiple lymphomas including Hodgkin lymphoma, peripheral T-cell lymphomas, mycosis fungoides, and relapsed/refractory B-cell lymphomas. The drug can be used as monotherapy or in combination with chemotherapy regimens depending on indication and disease status.
$3MPart D
PeakPeak lifecycle product with modest Part D spending ($3M in 2023) indicates mature market penetration; supply chain and operational roles suggest focus on manufacturing efficiency and distribution optimization rather than commercial expansion.
Mechanism of Action
CD30-directed Antibody Interactions
Pharmacologic Class:
CD30-directed Immunoconjugate
Indications (2)
Worked on ADCETRIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.